News Center

The latest news, insights and resources from Prothena

News Center

Donna-Lee Destouche, Head of Clinical Trial Management at Prothena, shares her perspective on supporting women and girls in science

Sunday marked International Day of Women and Girls in Science, but we at Prothena proudly celebrate women in our industry every day. Last fall, we heard from Ria Palarca and Nhu Truong on the importance of equal opportunity and a supportive workplace. Today, we’re excited to hear from Donna-Lee Destouche, as she shares advice on […]

Hear from Prothena CEO Gene Kinney on the progress made across the Alzheimer’s disease industry and his outlook for 2024

From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer’s disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer’s disease.   As we gear up for […]

Prothena Participates in the Walk to End Alzheimer’s

Held annually in more than 600 communities nationwide, the Alzheimer’s Association Walk to End Alzheimer’s® is the world’s largest event to raise awareness and funds for Alzheimer’s care, support and research. Last month, Prothenians showed their support by participating in walks across the globe – including Dublin, San Francisco, San Diego, Philadelphia and Boston. As […]

Reflecting on CTAD 2023, and the inspiring progress of Alzheimer’s disease R&D this year

Over 25 Prothenians attended the 16th annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting in October in Boston, Massachusetts. As always, it was inspiring to join experts in the space to discuss the latest advances in Alzheimer’s disease R&D as we work toward a shared goal of delivering better treatments to patients. Throughout the year […]

Ingrid Sprinz, PhD, Senior Medical Director, Hematology, answers questions about Prothena’s work in AL amyloidosis

Today, World Amyloidosis Day, we recognize people living with AL amyloidosis and their caregivers for their unwavering strength. We recently sat down with Ingrid Sprinz, PhD, Senior Medical Director, Hematology, to speak about current needs in the treatment of AL amyloidosis and Prothena’s progress in the space. Check out her perspective below.   Q: What […]

How Linda’s Persistence Played a Role in her AL Amyloidosis Diagnosis

“I want my kidneys biopsied.” In this powerful video, we hear about the journey to diagnosis from Linda, a daughter, mother and wife living with AL amyloidosis. After fifteen symptoms materialized over the course of just two years, Linda knew something wasn’t right. From severe back pain, sudden high blood pressure and uncontrollable vomiting, to […]

#ProthenaProud: Hear from Jun Lee, Associate Director, Clinical Science, as he shares his experience working at Prothena

Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.

Hear from Prothena’s Ria Palarca and Nhu Truong on women’s equality at Prothena

  Tomorrow, August 26, marks Women’s Equality Day, but each day we are proud of the women who work to advance science and truly impact patient lives. We recently had the chance to hear from Ria Palarca and Nhu Truong on the importance of equal opportunity and a supportive workplace. Check out their perspectives below. […]

Prothena’s presence at AAIC 2023 amidst a transformative time in the field of Alzheimer’s disease R&D

The Alzheimer’s disease space continues to buzz with news – advancements in the science and understanding of the disease, availability of new treatment options, and a newfound sense of hope for the Alzheimer’s community. In a recent interview with PharmaVoice, Prothena CEO Gene Kinney shares, “Science is an iterative process, and for a disease as […]

Mike and Donna on Fighting the Same Enemy

In this inspiring video, we hear how Mike’s amyloidosis has affected not only him, but his wife Donna and their marriage, too. In fact, they actually agree the diagnosis has brought them closer. Like many diseases, it is important to remember that amyloidosis changes the lives of more than just the patient. Donna, Mike’s primary […]

The Future of Alzheimer’s Disease Research, an OpEd by Donna Masterman, VP Medical Affairs, Neuroscience Lead, Prothena

Throughout the last year, we’ve seen some of the most significant breakthroughs to date in Alzheimer’s disease research, most notably—solidifying that anti-Aβ is a viable and clinically-sound treatment pathway. This is only the beginning, and we at Prothena are both proud and excited to be a part of developing the next generation of therapies for […]

An open letter from Francisco Lio, Senior Director, Global Program Manager

  Prothena is working to develop new treatments for people facing some of the world’s most devastating diseases, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. It’s a challenging mission that attracts people who are passionate and committed including Francisco Lio, our Senior Director, Global Program Manager, who manages interdisciplinary teams responsible for two promising Alzheimer’s […]

#ProthenaProud: Hear from Kendell Hardy, Senior Director, Human Resources, as she shares her experience working at Prothena

Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.

Suzanne Ostrander, Head of Clinical Operations at Prothena, answers questions about Prothena’s new partnership with Walgreens

  Q: Why is Prothena partnering with Walgreens? A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease […]

Prothena joins Rare Disease Company Coalition (RDCC)

Prothena recently joined the Rare Disease Company Coalition, a coalition of companies dedicated to discovering, developing, and delivering rare disease treatments for the patients we collectively serve. “We are happy to welcome Prothena to the Coalition; they join us in our work to advocate for policies that enable positive changes to be realized for the […]

Hear from Prothenians as they share their perspectives on what Rare Disease Day means to them

Q&A with Prothena’s Ansgar Conrad answers questions about the company’s partnership with ASPIRE

Q: What is ASPIRE? A: The Amyloidosis Stakeholder Partnerships for Impact Reach and Equity (ASPIRE) is a collaborative of biotech and pharmaceutical companies committed to improving diagnosis, systems of care, and health equity for patients suffering from amyloidosis, a rare disease caused by protein build-up. Q: What is ASPIRE’s goal? A: ASPIRE aims to accelerate […]

The impact of AL amyloidosis on work outcomes

Light chain (AL) amyloidosis is a rare and progressive disease that interferes with normal organ function and lead to failure of vital organs, like the heart. Currently, there are no approved therapies that significantly improve survival. The impact of amyloidosis goes beyond health. Patients with AL amyloidosis experience frequent overall loss of productivity, missed work […]

Hear from Prothena CEO Gene Kinney on why proteins are an essential part of life

Lab B-Roll